Trial
NCT03784599
T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
The Netherlands Cancer Institute
Collaborators
AstraZeneca; Roche Pharma AG
Condition
Carcinoma, Non-Small-Cell Lung
Intervention
Trastuzumab emtansine
Why stopped
insufficient effectiveness
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-10